TrialNature medicine2025
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.
Shanu Modi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
35 papers cite it
this paperpooled ittrialcites it